Abstract: ObjectiveTo investigate the effect of combination therapy with metformin and spironolactone in patients with polycystic ovary syndrome， including metabolism， endocrinerelated impacts， and subsequent ovulation rates.  MethodsA total of 60 patients with polycystic ovary syndrome were included in this study. All patients were randomly divided into A and B groups (30 cases each). Group A was treated with metformin 1 000 mg  everyday while group B was treated with metformin 1 000 mg combined with spironolactone 40 mg for 3 months. Then related indices were compared before and after treatment  between two groups. ResultsAfter 3 months of treatment， body mass and BMI were decreased in both groups and were significantly lower than those before treatment （P<0.05）; The waisthip ratio（WHR）  and FerrimanGallwey score were significantly lower after treatment in group B than in group A （P<0.05）.  After treatment， the levels of LH and T were decreased and were significantly lower than those before treatment （P<0.05）， however， the level of FSH was slightly changed （P>0.05）. After treatment， the level of insulin was significantly decreased in group A （P<0.05）， however， the level of glucose was no obvious difference（P>0.05）; in group B， the levels of insulin and glucose were significantly decreased (P<0.01 and P<0.05， respectively). After treatment， the levels of TG and LDLC were significantly decreased in group A （P<0.05）  and the levels of TG， LDLC and TC were significantly decreased in group B （P<0.05，P<0.01 and P<0.05， respectively）.ConclusionIn comparison with metformin alone， the combination therapy may be more effective for PCOS patients.

Key words: polycystic ovary syndrome, metformin, spironolactone